
NimBio
NimBio develops non-invasive diagnostic tools for early disease detection using advanced biosensing.
About
NimBio offers a proactive care solution for Inflammatory Bowel Disease (IBD) patients through its Inflammometer™ platform, which uses passive biosensing for real-time inflammation monitoring and early flare detection. This platform aims to provide effortless, remote, and personalized care for patients, while enhancing care delivery for hospitals and physicians, optimizing treatment for pharma, and reducing hospitalizations for payers. NimBio's solution focuses on identifying flare causes and offering therapeutic recommendations to prevent complications and optimize IBD management.
Key facts
At-a-glance profile data
- Website
- nimbio.ai
- Headquarters
- San Francisco, United States
- Founded
- 2019
- Employees
- 5
- Total funding
- -
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 7 Dec 2022 | Pre-Seed | Undisclosed | eHealth Ventures |
Tech stack
Detected on nimbio.ai, last scanned 7 Sept 2026. Run your own scan
- Email provider
- Google Workspace
Frequently asked
How many employees does NimBio have?
NimBio has approximately 5 people on record.